ALK signaling primes the DNA damage response sensitizing ALK-driven neuroblastoma to therapeutic ATR inhibition

Area of Science:

• Oncology
• Molecular Biology
• Cancer Genetics

Background:

• High-risk neuroblastoma (NB) presents a significant clinical challenge, often driven by MYCN and Anaplastic Lymphoma Kinase (ALK) alterations.
• These alterations induce replication stress, creating therapeutic vulnerabilities in cancer cells.

Purpose of the Study:

• To elucidate the molecular mechanism of a combined ATR/ALK inhibitor (ATRi/ALKi) strategy in neuroblastoma.
• To evaluate the efficacy of ATRi/ALKi combination therapy in preclinical neuroblastoma models.

Main Methods:

• Utilized genetically modified mouse neuroblastoma models.
• Investigated the molecular signaling pathways involving ATR, ALK, and CHK1.
• Assessed treatment responses and tumor cell differentiation following monotherapy versus combination therapy.

Main Results:

• ALK signaling phosphorylates ATR and CHK1, crucial for DNA damage response.
• ATRi monotherapy showed initial efficacy but led to relapse, while 14-day ALKi/ATRi combination therapy yielded sustained responses.
• Combined ATR/ALK inhibition induced robust tumor cell differentiation into neuronal/Schwann cell lineages.

Conclusions:

• Combined ATR/ALK inhibition represents a promising therapeutic strategy for high-risk neuroblastoma.
• ATR inhibition can promote neuroblastoma differentiation, offering a novel treatment avenue.
• This approach is particularly relevant for high-risk neuroblastoma patients with oncogene-induced replication stress.